Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Vladimir P. Chulanov"'
Autor:
Sergey N. Avdeev, Vladimir P. Chulanov, Ekaterina I. Alexeeva, Olga A. Aleshina, Aleksey V. Bereznikov, Oleg N. Kotenko, Aleksander M. Lila, Zinaida Yu. Mutovina, Elena N. Parovichnikova, Daria S. Fomina, Nadiya F. Frolova, Alexey O. Shevchenko
Publikováno v:
Терапевтический архив, Vol 95, Iss 8, Pp 722-729 (2023)
On July 3, 2023, an interdisciplinary Council of Experts The burden of COVID-19 in a heterogeneous population of immunocompromised patients post-pandemic realities was held in Moscow with leading experts in pulmonology, rheumatology, hematology, onco
Externí odkaz:
https://doaj.org/article/87994ce57ab2448b9f97ce142a57085f
Autor:
Marina S. Lebedkina, Daria S. Fomina, Zinaida Y. Mutovina, Ulyana A. Mаrkina, Pavel O. Bogomolov, Vladimir P. Chulanov, Mariana A. Lysenko, Ekaterina I. Alexeeva
Publikováno v:
Терапевтический архив, Vol 95, Iss 6, Pp 494-499 (2023)
Aim. To evaluate the efficacy and safety of a combination of virus-neutralizing monoclonal antibodies MAB (casirivimab and imdevimab) in patients with mild to moderate COVID-19 with risk factors in real word settings. Materials and methods. A non-
Externí odkaz:
https://doaj.org/article/eb72a7ef09da4ff099f9522bed183bf7
Publikováno v:
Терапевтический архив, Vol 95, Iss 1, Pp 66-77 (2023)
Aim. To evaluate pharmacoeconomic feasibility using of the tixagevimab and cilgavimab combination for pre-exposure prophylaxis of COVID-19 in immunocompromised patients. Materials and methods. Cost-effectiveness of tixagevimab and cilgavimab in pe
Externí odkaz:
https://doaj.org/article/746272428ec64d81a6a04a802ec8e8f2
Autor:
Natalia Yu. Pshenichnaya, Elena N. Kareva, Irina A. Leneva, Vilya A. Bulgakova, Irina E. Kravchenko, Irina V. Nikolaeva, Antonina I. Grekova, Antonina P. Ivanova, Larisa V. Puzyreva, Guzel M. Khasanova, Svetlana N. Orlova, Elena P. Tikhonova, Vladimir A. Petrov, Oleg V. Malinin, Natalia V. Kolaeva, Elena V. Volchkova, Nina N. Kanshina, Vladimir P. Chulanov
Publikováno v:
Терапевтический архив, Vol 93, Iss 11, Pp 1306-1315 (2021)
Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions
Externí odkaz:
https://doaj.org/article/880fd58841c14cb7b184ec79dd03505b
Autor:
Pavel O. Bogomolov, Vladimir T. Ivashkin, Alexey O. Bueverov, Igor V. Maev, Olga I. Sagalova, Snezhana S. Sleptsova, Nikolay D. Yushuk, Denis A. Gusev, Konstantin V. Zhdanov, Vladimir P. Chulanov
Publikováno v:
Терапевтический архив, Vol 93, Iss 11, Pp 1290-1299 (2021)
Aim. To study the efficacy and safety of bulevirtide, the HBV and HDV entry inhibitor. Materials and methods. Analysis of the results of using bulevirtide in randomized controlled open-label comparative studies MYR202 and MYR203 in 56 patients wit
Externí odkaz:
https://doaj.org/article/dd4f639c7df44744a2a36d995ab5afcd
Autor:
Artem P. Tkachuk, Evgeniia N. Bykonia, Liubov I. Popova, Denis A. Kleymenov, Maria A. Semashko, Vladimir P. Chulanov, Sergey B. Fitilev, Semyon L. Maksimov, Elena A. Smolyarchuk, Victor A. Manuylov, Daria V. Vasina, Vladimir A. Gushchin, Alexander L. Gintsburg
Publikováno v:
Vaccines, Vol 8, Iss 4, p 652 (2020)
GamTBvac is a candidate tuberculosis vaccine with two fusion proteins, containing Ag85a, ESAT6, CFP10, and a dextran-binding domain (DBD). Phase II of a double-blind, randomized, multicenter, placebo-controlled study in parallel groups in healthy adu
Externí odkaz:
https://doaj.org/article/6df5a455213341a6a73b051422a1a694
Autor:
Anna E. Tsygankova, Andrey N. Gerasimov, Svetlana A. Potekaeva, Svetlana V. Krasnova, Natalia A. Tsvetkova, Natalia V. Maloletneva, Elena V. Volchkova, Vladimir P. Chulanov
Publikováno v:
Epidemiology and Infectious Diseases. 27:148-163
BACKGROUND: No studies have examined the course and outcomes of coronavirus disease 2019 (COVID-19) in patients with advanced HIV infection, which prompted this analysis. AIM: To identify predictors of the adverse outcomes of COVID-19 in patients wit
Autor:
Vladimir P. Chulanov, Bulat A. Bakirov, Natalia N. Vezikova, Vladimir N. Gorodin, Marina V. Zhuravleva, Alena I. Zagrebneva, Igor G. Ivanov, Nikita V. Lomakin, Galina V. Lukina, Diana L. Moysova, Zinaida I. Mutovina
Publikováno v:
Terapevticheskii arkhiv. 94(8)
The Advisory Board chaired by the chief specialist in infectious diseases of the Ministry of Health of Russian Federation, Professor V.P. Chulanov was held on June 18, 2022 in Saint Petersburg. Aim. The main purpose of the Board was following discuss
Autor:
Pavel O. Bogomolov, Vladimir T. Ivashkin, Alexey O. Bueverov, Igor V. Maev, Olga I. Sagalova, Snezhana S. Sleptsova, Nikolay D. Yushuk, Denis A. Gusev, Konstantin V. Zhdanov, Vladimir P. Chulanov
Publikováno v:
Терапевтический архив, Vol 93, Iss 11, Pp 1290-1299 (2021)
To study the efficacy and safety of bulevirtide, the HBV and HDV entry inhibitor.Analysis of the results of using bulevirtide in randomized controlled open-label comparative studies MYR202 and MYR203 in 56 patients with chronic hepatitis D and compen
Autor:
Natalia Yu. Pshenichnaya, Elena N. Kareva, Irina A. Leneva, Vilya A. Bulgakova, Irina E. Kravchenko, Irina V. Nikolaeva, Antonina I. Grekova, Antonina P. Ivanova, Larisa V. Puzyreva, Guzel M. Khasanova, Svetlana N. Orlova, Elena P. Tikhonova, Vladimir A. Petrov, Oleg V. Malinin, Natalia V. Kolaeva, Elena V. Volchkova, Nina N. Kanshina, Vladimir P. Chulanov
Publikováno v:
Терапевтический архив, Vol 93, Iss 11, Pp 1306-1315 (2021)
An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness.The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men an